Recent Advances in Targeted Radionuclide Therapy of Cancers:@0.319158:0.035749:0.914575:0.035749:0.914575:0.019993:0.319158:0.019993:0.011680:0.012508:0.012450:0.012508:0.011738:0.006523:0.005330:0.014239:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.007466:0.005330:0.003848:0.011738:0.005330:0.007179:0.013143:0.005809:0.012950:0.012508:0.006523:0.012508:0.013181:0.005330:0.011680:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.005330:0.008197:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.012604:0.006042:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
27:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
complexed to Lu-177 or an alpha-emitting :@0.084242:0.096166:0.480480:0.096166:0.480480:0.080410:0.084242:0.080410:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.009236:0.012508:0.013181:0.004934:0.006523:0.012604:0.004928:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.004945:0.012604:0.005792:0.004926:0.013143:0.011738:0.004934:0.013143:0.003848:0.013123:0.011738:0.013143:0.006388:0.012508:0.018049:0.003848:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330
radionuclide such as Actinium 225 (Ac-225) :@0.084242:0.112636:0.480474:0.112636:0.480474:0.096880:0.084242:0.096880:0.005600:0.012950:0.012989:0.003656:0.012411:0.011545:0.011507:0.012257:0.003656:0.003656:0.012989:0.012315:0.004483:0.007274:0.011507:0.012257:0.011545:0.004474:0.012950:0.007274:0.004483:0.014047:0.012257:0.006331:0.003656:0.011545:0.003656:0.011507:0.017857:0.004474:0.010468:0.010468:0.010468:0.004474:0.006908:0.014047:0.012257:0.006196:0.010468:0.010468:0.010468:0.007102:0.005330
or Bismuth 213 (Bi-213) for radioligand ther-:@0.084242:0.129106:0.475152:0.129106:0.475152:0.113350:0.084242:0.113350:0.012604:0.005792:0.004661:0.011045:0.003848:0.007466:0.018049:0.011699:0.006523:0.011738:0.004664:0.010660:0.010660:0.010660:0.004676:0.007100:0.011045:0.003848:0.006388:0.010660:0.010660:0.010660:0.007100:0.004691:0.006042:0.012604:0.005792:0.004661:0.005792:0.013143:0.013181:0.003848:0.012604:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.004676:0.006523:0.011738:0.012508:0.005800:0.006388
apy of mCRPC.:@0.084242:0.145577:0.227868:0.145577:0.227868:0.129821:0.084242:0.129821:0.013143:0.013123:0.010314:0.005330:0.012604:0.006042:0.005330:0.018049:0.015644:0.011680:0.011392:0.015644:0.005330
8:@0.227856:0.139963:0.234071:0.139963:0.234071:0.130777:0.227856:0.130777:0.006215
PRLT may be considered in patients with :@0.102424:0.162054:0.480476:0.162054:0.480476:0.146298:0.102424:0.146298:0.011392:0.011680:0.007999:0.008197:0.005426:0.018049:0.013143:0.010314:0.005426:0.013123:0.012508:0.005426:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005717:0.012508:0.013181:0.005426:0.003848:0.011738:0.005426:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005426:0.015990:0.003848:0.006523:0.011738:0.005330
mCRPC  who  have exhausted or  do  not :@0.084240:0.178525:0.480505:0.178525:0.480505:0.162769:0.084240:0.162769:0.018049:0.015644:0.011680:0.011392:0.015644:0.005330:0.004181:0.015990:0.011738:0.012604:0.005330:0.004183:0.011738:0.013143:0.010660:0.012508:0.009525:0.012508:0.009236:0.011738:0.013143:0.011699:0.007466:0.006523:0.012508:0.013181:0.009525:0.012604:0.005792:0.005330:0.004179:0.013181:0.012604:0.005330:0.004183:0.011738:0.012604:0.006523:0.005330
tolerate approved therapies.:@0.084240:0.194995:0.354375:0.194995:0.354375:0.179239:0.084240:0.179239:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.006523:0.012508:0.005330:0.013143:0.013123:0.013123:0.005705:0.012604:0.010660:0.012508:0.013181:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.007466:0.005330
The following must be ensured before a :@0.084240:0.227935:0.480489:0.227935:0.480489:0.212180:0.084240:0.212180:0.008197:0.011738:0.012508:0.009198:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.009198:0.018049:0.011699:0.007466:0.006523:0.009198:0.013123:0.012508:0.009198:0.012508:0.011738:0.007466:0.011699:0.005711:0.012508:0.013181:0.009198:0.013123:0.012508:0.006042:0.012604:0.005709:0.012508:0.009198:0.013143:0.005330
patient is considered for PRLT.:@0.084240:0.244406:0.357132:0.244406:0.357132:0.228650:0.084240:0.228650:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.005330:0.003848:0.007466:0.005330:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005711:0.012508:0.013181:0.005330:0.006042:0.012604:0.005792:0.005330:0.011392:0.011680:0.007986:0.006831:0.005330
n   :@0.084242:0.257768:0.107051:0.257768:0.107051:0.249327:0.084242:0.249327:0.009762:0.003566:0.005914:0.003566
Ga-68 PSMA PET/CT showing tracer :@0.103485:0.260887:0.435359:0.260887:0.435359:0.245131:0.103485:0.245131:0.016779:0.013143:0.006388:0.010660:0.010660:0.005330:0.011392:0.009583:0.017684:0.014239:0.005330:0.011392:0.010314:0.008197:0.008409:0.015644:0.008197:0.005330:0.007466:0.011738:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.006523:0.005792:0.013143:0.012450:0.012508:0.005792:0.005330
uptake within lesions:@0.103485:0.277357:0.293965:0.277357:0.293965:0.261601:0.103485:0.261601:0.011699:0.013123:0.006523:0.013143:0.009660:0.012508:0.005330:0.015990:0.003848:0.006523:0.011738:0.003848:0.011738:0.005330:0.003848:0.012508:0.007466:0.003848:0.012604:0.011738:0.007466
n   :@0.084242:0.290712:0.107051:0.290712:0.107051:0.282272:0.084242:0.282272:0.009762:0.003566:0.005914:0.003566
Sufficient bone-marrow reserve, WBC :@0.103485:0.293831:0.453839:0.293831:0.453839:0.278075:0.103485:0.278075:0.009583:0.011699:0.006042:0.004686:0.004686:0.012450:0.003848:0.012508:0.011738:0.006523:0.005330:0.013123:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005694:0.012604:0.015990:0.005330:0.005705:0.012508:0.007466:0.012508:0.005792:0.010660:0.012508:0.005330:0.005330:0.018473:0.011045:0.015644:0.005330
>3,000/µl, platelets >75,000/µL:@0.103485:0.310301:0.380614:0.310301:0.380614:0.294545:0.103485:0.294545:0.011661:0.010660:0.005330:0.010660:0.010660:0.010660:0.008409:0.011084:0.003848:0.005330:0.005330:0.013123:0.003848:0.013143:0.006523:0.012508:0.003848:0.012508:0.006523:0.007466:0.005330:0.011661:0.010660:0.010660:0.005330:0.010660:0.010660:0.010660:0.008409:0.011084:0.008890
n   :@0.084242:0.323656:0.107051:0.323656:0.107051:0.315216:0.084242:0.315216:0.009762:0.003566:0.005914:0.003566
Sufficient renal function reserve defined :@0.103485:0.326775:0.477101:0.326775:0.477101:0.311019:0.103485:0.311019:0.009583:0.011699:0.006042:0.004686:0.004686:0.012450:0.003848:0.012508:0.011738:0.006523:0.005330:0.005702:0.012508:0.011738:0.013143:0.003848:0.005330:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005696:0.012508:0.007466:0.012508:0.005792:0.010660:0.012508:0.005330:0.013181:0.012508:0.004686:0.004686:0.011738:0.012508:0.013181:0.005330
as serum creatinine <2 times the upper :@0.103485:0.343246:0.468659:0.343246:0.468659:0.327490:0.103485:0.327490:0.013143:0.007466:0.005330:0.007466:0.012508:0.005792:0.011699:0.018049:0.005330:0.012450:0.005707:0.012508:0.013143:0.006523:0.003848:0.011738:0.003848:0.011738:0.012508:0.005330:0.011661:0.010660:0.005330:0.006523:0.003848:0.018049:0.012508:0.007466:0.005330:0.006523:0.011738:0.012508:0.005330:0.011699:0.013123:0.013123:0.012508:0.005792:0.005330
limit of normal:@0.103485:0.359716:0.234606:0.359716:0.234606:0.343960:0.103485:0.343960:0.003848:0.003848:0.018049:0.003848:0.006523:0.005330:0.012604:0.006042:0.005330:0.011738:0.012604:0.006315:0.018049:0.013143:0.003848
n   :@0.084242:0.373073:0.107051:0.373073:0.107051:0.364632:0.084242:0.364632:0.009762:0.003566:0.005914:0.003566
Renal scintigraphy documenting good :@0.103485:0.376192:0.469283:0.376192:0.469283:0.360436:0.103485:0.360436:0.011680:0.012508:0.011738:0.013143:0.003848:0.005330:0.007466:0.012450:0.003848:0.011738:0.006523:0.003848:0.012950:0.005792:0.013143:0.013123:0.011738:0.010314:0.005330:0.013181:0.012604:0.012450:0.011699:0.018049:0.012508:0.011738:0.006523:0.003848:0.011738:0.012950:0.005330:0.012950:0.012604:0.012604:0.013181:0.005330
renal function and absence of urinary :@0.103485:0.392662:0.461026:0.392662:0.461026:0.376906:0.103485:0.376906:0.005713:0.012508:0.011738:0.013143:0.003848:0.005330:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.013143:0.011738:0.013181:0.005330:0.013143:0.013123:0.007466:0.012508:0.011738:0.012450:0.012508:0.005330:0.012604:0.006042:0.005330:0.011699:0.005792:0.003848:0.011738:0.013143:0.005792:0.010314:0.005330
tract obstruction:@0.103485:0.409132:0.257616:0.409132:0.257616:0.393376:0.103485:0.393376:0.006523:0.005792:0.013143:0.012450:0.006523:0.005330:0.012604:0.013123:0.007466:0.006523:0.005792:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738
n   :@0.084242:0.422489:0.107051:0.422489:0.107051:0.414049:0.084242:0.414049:0.009762:0.003566:0.005914:0.003566
Discontinuation of other potentially :@0.103485:0.425608:0.434724:0.425608:0.434724:0.409852:0.103485:0.409852:0.014316:0.003848:0.007466:0.012450:0.012604:0.011738:0.006523:0.003848:0.011738:0.011699:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.012604:0.006042:0.005330:0.012604:0.006523:0.011738:0.012508:0.005792:0.005330:0.013123:0.012604:0.006523:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.003848:0.010314:0.005330
myelosuppressive therapies for six :@0.103485:0.442078:0.419353:0.442078:0.419353:0.426322:0.103485:0.426322:0.018049:0.010314:0.012508:0.003848:0.012604:0.007466:0.011699:0.013123:0.013123:0.005719:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.007466:0.005330:0.006042:0.012604:0.005792:0.005330:0.007466:0.003848:0.009236:0.005330
weeks before commencement of PRLT.:@0.103485:0.458549:0.466445:0.458549:0.466445:0.442793:0.103485:0.442793:0.015990:0.012508:0.012508:0.009660:0.007466:0.005330:0.013123:0.012508:0.006042:0.012604:0.005705:0.012508:0.005330:0.012450:0.012604:0.018049:0.018049:0.012508:0.011738:0.012450:0.012508:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042:0.005330:0.011392:0.011680:0.007966:0.006831:0.005330
The  therapeutic  agent  in  PRLT  is  adminis-:@0.084242:0.491489:0.475165:0.491489:0.475165:0.475733:0.084242:0.475733:0.007812:0.011353:0.012123:0.005330:0.004838:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.012123:0.011315:0.006138:0.003464:0.012065:0.005330:0.004838:0.012758:0.012565:0.012123:0.011353:0.006138:0.005330:0.004839:0.003464:0.011353:0.005330:0.004839:0.011007:0.011295:0.007620:0.007812:0.005330:0.004838:0.003464:0.007081:0.005330:0.004839:0.012758:0.012796:0.017665:0.003464:0.011353:0.003464:0.007081:0.006388
tered intravenously with less stringent need :@0.084242:0.507960:0.480501:0.507960:0.480501:0.492204:0.084242:0.492204:0.006138:0.012123:0.005328:0.012123:0.012796:0.006966:0.003464:0.011353:0.006138:0.005407:0.012758:0.010275:0.012123:0.011353:0.012219:0.011315:0.007081:0.003464:0.009929:0.006966:0.015606:0.003464:0.006138:0.011353:0.006966:0.003464:0.012123:0.007081:0.007081:0.006966:0.007081:0.006138:0.005407:0.003464:0.011353:0.012565:0.012123:0.011353:0.006138:0.006966:0.011353:0.012123:0.012123:0.013183:0.005330
for amino acid co-administration due to a :@0.084242:0.524430:0.480503:0.524430:0.480503:0.508674:0.084242:0.508674:0.005657:0.012219:0.005407:0.007505:0.012758:0.017665:0.003464:0.011353:0.012219:0.007505:0.012758:0.012065:0.003464:0.012796:0.007505:0.012065:0.012219:0.006004:0.012758:0.012796:0.017665:0.003464:0.011353:0.003464:0.007081:0.006138:0.005407:0.012758:0.006138:0.003464:0.012219:0.011353:0.007505:0.012796:0.011315:0.012123:0.007505:0.006138:0.012219:0.007505:0.013144:0.005330
lower risk of renal toxicity compared with :@0.084242:0.540900:0.480453:0.540900:0.480453:0.525144:0.084242:0.525144:0.003464:0.012219:0.015606:0.012123:0.005407:0.009506:0.005407:0.003464:0.007081:0.009275:0.009506:0.012219:0.005657:0.009506:0.005326:0.012123:0.011353:0.012758:0.003464:0.009506:0.006138:0.012219:0.008852:0.003464:0.012065:0.003464:0.006138:0.009929:0.009506:0.012065:0.012219:0.017665:0.012738:0.012758:0.005328:0.012123:0.012796:0.009506:0.015606:0.003464:0.006138:0.011734:0.005330
PRRNT in NETs. Four to six cycles are admin-:@0.084242:0.557370:0.475148:0.557370:0.475148:0.541615:0.084242:0.541615:0.011007:0.011295:0.011295:0.013855:0.007812:0.006331:0.003464:0.011353:0.006331:0.013855:0.009929:0.007368:0.007081:0.004945:0.006331:0.008948:0.012219:0.011315:0.005407:0.006331:0.006138:0.012219:0.006331:0.007081:0.003464:0.008852:0.006331:0.012065:0.009929:0.012065:0.003464:0.012123:0.007081:0.006331:0.012758:0.005328:0.012123:0.006331:0.012758:0.012796:0.017665:0.003464:0.011353:0.006388
istered at eight- to 12-week intervals. Con-:@0.084242:0.573841:0.475129:0.573841:0.475129:0.558085:0.084242:0.558085:0.003464:0.007081:0.006138:0.012123:0.005326:0.012123:0.012796:0.007505:0.012758:0.006138:0.007505:0.012123:0.003464:0.012565:0.011353:0.006138:0.006004:0.007505:0.006138:0.012219:0.007505:0.010275:0.010275:0.006004:0.015606:0.012123:0.012123:0.009275:0.007505:0.003464:0.011353:0.006138:0.012123:0.005407:0.010275:0.012758:0.003464:0.007081:0.004945:0.007505:0.015259:0.012219:0.011353:0.006388
comitant use of androgen deprivation may :@0.084242:0.590311:0.480484:0.590311:0.480484:0.574555:0.084242:0.574555:0.012065:0.012219:0.017665:0.003464:0.006138:0.012758:0.011353:0.006138:0.005349:0.011315:0.007081:0.012123:0.005349:0.012219:0.005657:0.005349:0.012758:0.011353:0.012796:0.005328:0.012219:0.012565:0.012123:0.011353:0.005349:0.012796:0.012123:0.012738:0.005407:0.003464:0.010275:0.012758:0.006138:0.003464:0.012219:0.011353:0.005349:0.017665:0.012758:0.010318:0.005330
upregulate the expression of PSMA glyco-:@0.084242:0.606781:0.475146:0.606781:0.475146:0.591025:0.084242:0.591025:0.011315:0.012738:0.005326:0.012123:0.012565:0.011315:0.003464:0.012758:0.006138:0.012123:0.008640:0.006138:0.011353:0.012123:0.008640:0.012123:0.008852:0.012738:0.005328:0.012123:0.007081:0.007081:0.003464:0.012219:0.011353:0.008640:0.012219:0.005657:0.008640:0.011007:0.009198:0.017299:0.013855:0.008640:0.012565:0.003464:0.009929:0.012065:0.012219:0.006388
protein, hence this therapy can be contin-:@0.084242:0.623252:0.475169:0.623252:0.475169:0.607496:0.084242:0.607496:0.012738:0.005328:0.012219:0.006138:0.012123:0.003464:0.011353:0.004945:0.006850:0.011353:0.012123:0.011353:0.012065:0.012123:0.006850:0.006138:0.011353:0.003464:0.007081:0.006850:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.009929:0.006850:0.012065:0.012758:0.011353:0.006850:0.012738:0.012123:0.006850:0.012065:0.012219:0.011353:0.006138:0.003464:0.011353:0.006388
ued in patients being treated with PRLT.:@0.084242:0.639722:0.434662:0.639722:0.434662:0.623966:0.084242:0.623966:0.011315:0.012123:0.012796:0.004945:0.003464:0.011353:0.004945:0.012738:0.012758:0.006138:0.003464:0.012123:0.011353:0.006138:0.007081:0.004945:0.012738:0.012123:0.003464:0.011353:0.012565:0.004945:0.006138:0.005326:0.012123:0.012758:0.006138:0.012123:0.012796:0.004945:0.015606:0.003464:0.006138:0.011353:0.004945:0.011007:0.011295:0.007620:0.006446:0.005330
The efficacy and safety profile of Lu-177 :@0.102426:0.656192:0.480474:0.656192:0.480474:0.640436:0.102426:0.640436:0.008197:0.011738:0.012508:0.005855:0.012508:0.006042:0.004686:0.004686:0.012450:0.013143:0.012450:0.010314:0.005861:0.013143:0.011738:0.013181:0.005865:0.007466:0.013143:0.006042:0.012508:0.006523:0.010314:0.005869:0.013123:0.005715:0.012604:0.004686:0.004686:0.003848:0.012508:0.005857:0.012604:0.006042:0.005859:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.005330
PSMA for PRLT in metastatic prostate can-:@0.084242:0.672663:0.475158:0.672663:0.475158:0.656907:0.084242:0.656907:0.011392:0.009583:0.017684:0.014239:0.006198:0.006042:0.012604:0.005792:0.006204:0.011392:0.011680:0.007999:0.008197:0.006204:0.003848:0.011738:0.006206:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.006215:0.013123:0.005711:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.006204:0.012450:0.013143:0.011738:0.006388
cer were demonstrated in a multicentre :@0.084242:0.689133:0.480474:0.689133:0.480474:0.673377:0.084242:0.673377:0.012450:0.012508:0.005792:0.009217:0.015990:0.012508:0.005713:0.012508:0.009217:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.009217:0.003848:0.011738:0.009217:0.013143:0.009217:0.018049:0.011699:0.003848:0.006523:0.003848:0.012450:0.012508:0.011738:0.006523:0.005709:0.012508:0.005330
German  study of  145 patients  who  had :@0.084242:0.705603:0.480484:0.705603:0.480484:0.689847:0.084242:0.689847:0.016779:0.012508:0.006323:0.018049:0.013143:0.011738:0.005330:0.004551:0.007466:0.006523:0.011699:0.013181:0.010314:0.009891:0.012604:0.006042:0.005330:0.004547:0.010660:0.010660:0.010660:0.009891:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.004551:0.015990:0.011738:0.012604:0.005330:0.004545:0.011738:0.013143:0.013181:0.005330
one to four cycles of Lu-177 PSMA. Grade :@0.084242:0.722074:0.480480:0.722074:0.480480:0.706318:0.084242:0.706318:0.012604:0.011738:0.012508:0.006071:0.006523:0.012604:0.006071:0.006042:0.012604:0.011699:0.005792:0.006069:0.012450:0.010314:0.012450:0.003848:0.012508:0.007466:0.006081:0.012604:0.006042:0.006081:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.006081:0.011392:0.009583:0.017684:0.014239:0.005330:0.006071:0.016779:0.005792:0.013143:0.013181:0.012508:0.005330
3/4 anaemia occurred  in  15 patients, :@0.084242:0.738544:0.480499:0.738544:0.480499:0.722788:0.084242:0.722788:0.010660:0.008409:0.010660:0.014432:0.013143:0.011738:0.013143:0.012508:0.018049:0.003848:0.013143:0.014432:0.012604:0.012450:0.012450:0.011699:0.005792:0.005702:0.012508:0.013181:0.005330:0.009088:0.003848:0.011738:0.005330:0.009088:0.010660:0.010660:0.014432:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005330
grade 3/4 thrombocytopaenia in five pa-:@0.084242:0.755014:0.475148:0.755014:0.475148:0.739258:0.084242:0.739258:0.012950:0.005792:0.013143:0.013181:0.012508:0.006610:0.010660:0.008409:0.010660:0.006621:0.006523:0.011738:0.005707:0.012604:0.018049:0.013123:0.012604:0.012450:0.010314:0.006523:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.006617:0.003848:0.011738:0.006617:0.004686:0.004686:0.010660:0.012508:0.006616:0.013123:0.013143:0.006388
tients. No therapy-related death was seen. :@0.084242:0.771485:0.480497:0.771485:0.480497:0.755729:0.084242:0.755729:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.003987:0.014239:0.012604:0.003987:0.006523:0.011738:0.012508:0.005792:0.013133:0.013123:0.010314:0.006388:0.005719:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.003993:0.013181:0.012508:0.013143:0.006523:0.011738:0.003987:0.015990:0.013143:0.007466:0.004002:0.007466:0.012508:0.012508:0.011738:0.005330:0.005330
A low pre-therapy blood-cell count  was :@0.084242:0.787955:0.480457:0.787955:0.480457:0.772199:0.084242:0.772199:0.014239:0.009467:0.003848:0.012604:0.015990:0.009467:0.013123:0.005713:0.012508:0.006388:0.006523:0.011738:0.012508:0.005778:0.013143:0.013123:0.010314:0.009467:0.013123:0.003848:0.012604:0.012604:0.013181:0.006388:0.012450:0.012508:0.003848:0.003848:0.009467:0.012450:0.012604:0.011699:0.011738:0.006523:0.005330:0.004127:0.015990:0.013143:0.007466:0.005330
predictive of haematotoxicity. Response :@0.084242:0.804425:0.480472:0.804425:0.480472:0.788669:0.084242:0.788669:0.013123:0.005715:0.012508:0.013181:0.003848:0.012450:0.006523:0.003848:0.010660:0.012508:0.010141:0.012604:0.006042:0.010141:0.011738:0.013143:0.012508:0.018049:0.013143:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006514:0.010314:0.005330:0.010141:0.011680:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330
was assessed, using a fall in PSA level. 45% :@0.084242:0.820895:0.480490:0.820895:0.480490:0.805140:0.084242:0.805140:0.015990:0.013143:0.007466:0.005542:0.013143:0.007466:0.007466:0.012508:0.007466:0.007466:0.012508:0.013181:0.005330:0.005542:0.011699:0.007466:0.003848:0.011738:0.012950:0.005542:0.013143:0.005542:0.006042:0.013143:0.003848:0.003848:0.005542:0.003848:0.011738:0.005542:0.011392:0.009583:0.014239:0.005530:0.003848:0.012508:0.010660:0.012508:0.003848:0.005330:0.005542:0.010660:0.010660:0.014913:0.005330
of evaluable patients demonstrated a PSA :@0.084242:0.837366:0.480492:0.837366:0.480492:0.821610:0.084242:0.821610:0.012604:0.006042:0.004272:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.013123:0.003848:0.012508:0.004272:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004272:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.004262:0.013143:0.004272:0.011392:0.009583:0.014239:0.005330
decline of at least 50% – biochemical re-:@0.084242:0.853836:0.475110:0.853836:0.475110:0.838080:0.084242:0.838080:0.013181:0.012508:0.012450:0.003848:0.003848:0.011738:0.012508:0.007274:0.012604:0.006042:0.007274:0.013143:0.006523:0.007274:0.003848:0.012508:0.013143:0.007466:0.006523:0.007274:0.010660:0.010660:0.014913:0.007274:0.009621:0.007274:0.013123:0.003848:0.012604:0.012450:0.011738:0.012508:0.018049:0.003848:0.012450:0.013143:0.003848:0.007274:0.005711:0.012508:0.006388
sponders. A PSA decline of any number :@0.084242:0.870306:0.480482:0.870306:0.480482:0.854550:0.084242:0.854550:0.007466:0.013123:0.012604:0.011738:0.013181:0.012508:0.005792:0.007466:0.005330:0.009236:0.014239:0.009236:0.011392:0.009583:0.014239:0.009236:0.013181:0.012508:0.012450:0.003848:0.003848:0.011738:0.012508:0.009236:0.012604:0.006042:0.009236:0.013143:0.011738:0.010314:0.009236:0.011738:0.011699:0.018049:0.013123:0.012508:0.005792:0.005330
was seen in 60% of  patients.  Patient-re-:@0.084242:0.886777:0.475158:0.886827:0.475158:0.871071:0.084242:0.871021:0.015990:0.013143:0.007466:0.009429:0.007466:0.012508:0.012508:0.011738:0.009429:0.003848:0.011738:0.009429:0.010660:0.010660:0.014913:0.009429:0.012604:0.006042:0.005330:0.004089:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.006202:0.009429:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.006388:0.005705:0.012508:-0.281237
9:@0.362848:0.881208:0.369063:0.881208:0.369063:0.872023:0.362848:0.872023:0.006215
ported outcome has been evaluated for :@0.084239:0.903298:0.480498:0.903298:0.480498:0.887542:0.084239:0.887542:0.013123:0.012604:0.005792:0.006523:0.012508:0.013181:0.007370:0.012604:0.011699:0.006523:0.012450:0.012604:0.018049:0.012508:0.007364:0.011738:0.013143:0.007466:0.007389:0.013123:0.012508:0.012508:0.011738:0.007376:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.006523:0.012508:0.013181:0.007389:0.006042:0.012604:0.005792:0.005330
in multiple studies. PRLT with Lu-177 PSMA :@0.084239:0.919768:0.480498:0.919768:0.480498:0.904012:0.084239:0.904012:0.003848:0.011738:0.007437:0.018049:0.011699:0.003848:0.006523:0.003848:0.013123:0.003848:0.012508:0.007447:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466:0.005330:0.007447:0.011392:0.011680:0.008001:0.008197:0.007431:0.015990:0.003848:0.006523:0.011738:0.007437:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.007447:0.011392:0.009583:0.017684:0.014239:0.005330
led  to  significant  pain  relief  in  33-70%  of :@0.084239:0.936238:0.480482:0.936238:0.480482:0.920482:0.084239:0.920482:0.003848:0.012508:0.013181:0.005330:0.003910:0.006523:0.012604:0.005330:0.003900:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.005330:0.003906:0.013123:0.013143:0.003848:0.011738:0.005330:0.003912:0.005713:0.012508:0.003848:0.003848:0.012508:0.006042:0.005330:0.003910:0.003848:0.011738:0.005330:0.003908:0.010660:0.010660:0.006388:0.010660:0.010660:0.014913:0.005330:0.003922:0.012604:0.006042:0.005330
mCRPC patients, improvement in quality :@0.523639:0.096160:0.919864:0.096160:0.919864:0.080404:0.523639:0.080404:0.018049:0.015644:0.011680:0.011392:0.015644:0.008717:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.008717:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.018049:0.012508:0.011738:0.006523:0.008717:0.003848:0.011738:0.008717:0.013123:0.011699:0.013143:0.003848:0.003848:0.006523:0.010314:0.005330
of life in 60% and an improvement in per-:@0.523639:0.112511:0.914526:0.112511:0.914526:0.096755:0.523639:0.096755:0.012604:0.006042:0.006562:0.003848:0.003848:0.006042:0.012508:0.006562:0.003848:0.011738:0.006562:0.010660:0.010660:0.014913:0.006573:0.013143:0.011738:0.013181:0.006562:0.013143:0.011738:0.006562:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.018049:0.012508:0.011738:0.006523:0.006562:0.003848:0.011738:0.006562:0.013123:0.012508:0.005792:0.006388
formance status in 74% of patients.:@0.523639:0.128862:0.846631:0.128862:0.846631:0.113106:0.523639:0.113106:0.006042:0.012604:0.006319:0.018049:0.013143:0.011738:0.012450:0.012508:0.005330:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466:0.005330:0.003848:0.011738:0.005330:0.010660:0.010660:0.014913:0.005330:0.012604:0.006042:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
10:@0.846613:0.123260:0.859043:0.123260:0.859043:0.114075:0.846613:0.114075:0.006215:0.006215
Xerostomia is a potential side effect due :@0.541818:0.145236:0.919896:0.145236:0.919896:0.129480:0.541818:0.129480:0.011719:0.012508:0.005709:0.012604:0.007466:0.006523:0.012604:0.018049:0.003848:0.013143:0.004951:0.003848:0.007466:0.004965:0.013143:0.004965:0.013123:0.012604:0.006523:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.004951:0.007466:0.003848:0.013181:0.012508:0.004965:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.004947:0.013181:0.011699:0.012508:0.005330
to high expression of the PSMA glycopro-:@0.523634:0.161587:0.914545:0.161587:0.914545:0.145832:0.523634:0.145832:0.006523:0.012604:0.007164:0.011738:0.003848:0.012950:0.011738:0.007166:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.007168:0.012604:0.006042:0.007166:0.006523:0.011738:0.012508:0.007162:0.011392:0.009583:0.017684:0.014239:0.007166:0.012950:0.003848:0.010314:0.012450:0.012604:0.013123:0.005715:0.012604:0.006388
tein in the salivary glands. Xerostomia is :@0.523634:0.177939:0.919842:0.177939:0.919842:0.162183:0.523634:0.162183:0.006523:0.012508:0.003848:0.011738:0.009756:0.003848:0.011738:0.009756:0.006523:0.011738:0.012508:0.009756:0.007466:0.013143:0.003848:0.003862:0.010660:0.013143:0.005792:0.010314:0.009756:0.012950:0.003848:0.013143:0.011738:0.013181:0.007466:0.005330:0.009756:0.011719:0.012508:0.005709:0.012604:0.007466:0.006523:0.012604:0.018049:0.003848:0.013143:0.009756:0.003848:0.007466:0.005330
commonly mild and reversible.:@0.523634:0.194290:0.809568:0.194290:0.809568:0.178534:0.523634:0.178534:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.003848:0.010314:0.005330:0.018049:0.003848:0.003848:0.013181:0.005330:0.013143:0.011738:0.013181:0.005330:0.005707:0.012508:0.010660:0.012508:0.005792:0.007466:0.003848:0.013123:0.003848:0.012508:0.005330
Due to the densely ionising ability of al-:@0.541818:0.210641:0.914543:0.210641:0.914543:0.194885:0.541818:0.194885:0.014316:0.011699:0.012508:0.006860:0.006523:0.012604:0.006852:0.006523:0.011738:0.012508:0.006854:0.013181:0.012508:0.011738:0.007466:0.012508:0.003848:0.010314:0.006870:0.003848:0.012604:0.011738:0.003848:0.007466:0.003848:0.011738:0.012950:0.006870:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.006870:0.012604:0.006042:0.006854:0.013143:0.003848:0.006388
pha particles and their potential to cause :@0.523634:0.226992:0.919879:0.226992:0.919879:0.211237:0.523634:0.211237:0.013123:0.011738:0.013143:0.005917:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.003848:0.012508:0.007466:0.005917:0.013143:0.011738:0.013181:0.005913:0.006523:0.011738:0.012508:0.003848:0.005792:0.005905:0.013123:0.012604:0.006523:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.005927:0.006523:0.012604:0.005909:0.012450:0.013143:0.011699:0.007466:0.012508:0.005330
more  lethal damage to  the  cancer  cells :@0.523634:0.243344:0.919873:0.243344:0.919873:0.227588:0.523634:0.227588:0.018049:0.012604:0.005709:0.012508:0.005330:0.002896:0.003848:0.012508:0.006523:0.011738:0.013143:0.003848:0.008236:0.013181:0.013143:0.018049:0.013143:0.012950:0.012508:0.008236:0.006523:0.012604:0.005330:0.002892:0.006523:0.011738:0.012508:0.005330:0.002890:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.002892:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330
(due to double-stranded DNA damage) :@0.523634:0.259695:0.919892:0.259695:0.919892:0.243939:0.523634:0.243939:0.007100:0.013181:0.011699:0.012508:0.009390:0.006523:0.012604:0.009390:0.013181:0.012604:0.011699:0.013123:0.003848:0.012508:0.006388:0.007466:0.006523:0.005792:0.013143:0.011738:0.013181:0.012508:0.013181:0.009390:0.014316:0.014239:0.014239:0.009390:0.013181:0.013143:0.018049:0.013143:0.012950:0.012508:0.007100:0.005330
than beta particles, interest is now focused :@0.523634:0.276046:0.919867:0.276046:0.919867:0.260290:0.523634:0.260290:0.006523:0.011738:0.013143:0.011738:0.004002:0.013123:0.012508:0.006523:0.013143:0.004002:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.003848:0.012508:0.007466:0.005330:0.004002:0.003848:0.011738:0.006523:0.012508:0.005709:0.012508:0.007466:0.006523:0.004002:0.003848:0.007466:0.004002:0.011738:0.012604:0.015990:0.004002:0.006042:0.012604:0.012450:0.011699:0.007466:0.012508:0.013181:0.005330
on the use of alpha-emitting radionuclides :@0.523634:0.292397:0.919873:0.292397:0.919873:0.276642:0.523634:0.276642:0.012604:0.011738:0.004560:0.006523:0.011738:0.012508:0.004560:0.011699:0.007466:0.012508:0.004560:0.012604:0.006042:0.004560:0.013143:0.003848:0.013123:0.011738:0.013143:0.006388:0.012508:0.018049:0.003848:0.006523:0.006523:0.003848:0.011738:0.012950:0.004560:0.005792:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.007466:0.005330
complexed to PSMA ligand  for PRLT of :@0.523634:0.308749:0.919879:0.308749:0.919879:0.292993:0.523634:0.292993:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.009236:0.012508:0.013181:0.011719:0.006523:0.012604:0.011719:0.011392:0.009583:0.017684:0.014239:0.011719:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.005330:0.006400:0.006042:0.012604:0.005792:0.011719:0.011392:0.011680:0.007999:0.008197:0.011719:0.012604:0.006042:0.005330
metastatic prostate carcinoma. The two :@0.523634:0.325100:0.919892:0.325100:0.919892:0.309344:0.523634:0.309344:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.009294:0.013123:0.005715:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.009294:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.009294:0.008197:0.011738:0.012508:0.009294:0.006523:0.015990:0.012604:0.005330
most commonly used radionuclides are :@0.523634:0.341451:0.919890:0.341451:0.919890:0.325695:0.523634:0.325695:0.018049:0.012604:0.007466:0.006523:0.011276:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.003848:0.010314:0.011276:0.011699:0.007466:0.012508:0.013181:0.011276:0.005792:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.007466:0.011276:0.013143:0.005713:0.012508:0.005330
Bismuth 213 (Bi-213) and Actinium 225 (Ac-:@0.523634:0.357802:0.914530:0.357802:0.914530:0.342047:0.523634:0.342047:0.011045:0.003848:0.007466:0.018049:0.011699:0.006523:0.011738:0.004734:0.010660:0.010660:0.010660:0.004749:0.007100:0.011045:0.003848:0.006400:0.010660:0.010660:0.010660:0.007100:0.004753:0.013143:0.011738:0.013181:0.004734:0.014239:0.012450:0.006523:0.003848:0.011738:0.003848:0.011699:0.018049:0.004734:0.010660:0.010660:0.010660:0.004751:0.007100:0.014239:0.012450:0.006388
225) (see Figure 2). The longer half-life of :@0.523634:0.374154:0.919887:0.374154:0.919887:0.358398:0.523634:0.358398:0.010660:0.010660:0.010660:0.007100:0.007889:0.007100:0.007466:0.012508:0.012508:0.007889:0.009333:0.003848:0.012950:0.011699:0.005709:0.012508:0.007880:0.010660:0.007100:0.005330:0.007889:0.008197:0.011738:0.012508:0.007872:0.003848:0.012604:0.011738:0.012950:0.012508:0.005792:0.007878:0.011738:0.013143:0.003848:0.006042:0.006388:0.003848:0.003848:0.006042:0.012508:0.007889:0.012604:0.006042:0.005330
Ac-225 of 10 days compared with 46 min-:@0.523634:0.390505:0.914558:0.390505:0.914558:0.374749:0.523634:0.374749:0.014239:0.012450:0.006388:0.010660:0.010660:0.010660:0.005946:0.012604:0.006042:0.005931:0.010660:0.010660:0.005946:0.013181:0.013143:0.010314:0.007466:0.005946:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.005932:0.015990:0.003848:0.006523:0.011738:0.005934:0.010660:0.010660:0.005946:0.018049:0.003848:0.011738:0.006388
utes  of  Bi-213 makes  it  a  more  effective :@0.523634:0.406856:0.919865:0.406856:0.919865:0.391100:0.523634:0.391100:0.011699:0.006523:0.012508:0.007466:0.005330:0.003872:0.012604:0.006042:0.005330:0.003872:0.011045:0.003848:0.006388:0.010660:0.010660:0.010660:0.009217:0.018049:0.013143:0.009660:0.012508:0.007466:0.005330:0.003877:0.003848:0.006523:0.005330:0.003877:0.013143:0.005330:0.003875:0.018049:0.012604:0.005709:0.012508:0.005330:0.003873:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.005330
therapeutic radionuclide. Alpha particles :@0.523634:0.423207:0.919873:0.423207:0.919873:0.407452:0.523634:0.407452:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.012508:0.011699:0.006523:0.003848:0.012450:0.007697:0.005792:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.005330:0.007697:0.014239:0.003848:0.013123:0.011738:0.013143:0.007697:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.003848:0.012508:0.007466:0.005330
are heavy and only travel a short distance :@0.523634:0.439559:0.919892:0.439559:0.919892:0.423803:0.523634:0.423803:0.013143:0.005715:0.012508:0.004859:0.011738:0.012508:0.013143:0.010660:0.010314:0.004868:0.013143:0.011738:0.013181:0.004868:0.012604:0.011738:0.003848:0.010314:0.004859:0.006523:0.005792:0.013143:0.010660:0.012508:0.003848:0.004868:0.013143:0.004868:0.007466:0.011738:0.012604:0.005792:0.006523:0.004849:0.013181:0.003848:0.007466:0.006523:0.013143:0.011738:0.012450:0.012508:0.005330
in the  tissue. This accounts  for  the  lower :@0.523634:0.455910:0.919900:0.455910:0.919900:0.440154:0.523634:0.440154:0.003848:0.011738:0.009217:0.006523:0.011738:0.012508:0.005330:0.003873:0.006523:0.003848:0.007466:0.007466:0.011699:0.012508:0.005330:0.009217:0.008197:0.011738:0.003848:0.007466:0.009217:0.013143:0.012450:0.012450:0.012604:0.011699:0.011738:0.006523:0.007466:0.005330:0.003873:0.006042:0.012604:0.005792:0.005330:0.003877:0.006523:0.011738:0.012508:0.005330:0.003873:0.003848:0.012604:0.015990:0.012508:0.005792:0.005330
side effects associated with their use. Ac-:@0.523634:0.472261:0.914531:0.472261:0.914531:0.456505:0.523634:0.456505:0.007466:0.003848:0.013181:0.012508:0.006573:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.006562:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.006562:0.015990:0.003848:0.006523:0.011738:0.006562:0.006523:0.011738:0.012508:0.003848:0.005792:0.006562:0.011699:0.007466:0.012508:0.005330:0.006562:0.014239:0.012450:0.006388
225 PSMA  is now  being used in patients :@0.523634:0.488612:0.919873:0.488612:0.919873:0.472857:0.523634:0.472857:0.010660:0.010660:0.010660:0.009275:0.011392:0.009583:0.017684:0.014239:0.005330:0.003935:0.003848:0.007466:0.009275:0.011738:0.012604:0.015990:0.005330:0.003935:0.013123:0.012508:0.003848:0.011738:0.012950:0.009275:0.011699:0.007466:0.012508:0.013181:0.009275:0.003848:0.011738:0.009275:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
whose disease is refractory to Lu-177 PSMA :@0.523634:0.504964:0.919879:0.504964:0.919879:0.489208:0.523634:0.489208:0.015990:0.011738:0.012604:0.007466:0.012508:0.004547:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.004560:0.003848:0.007466:0.004560:0.005713:0.012508:0.006042:0.005792:0.013143:0.012450:0.006523:0.012604:0.005792:0.010314:0.004537:0.006523:0.012604:0.004547:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.004560:0.011392:0.009583:0.017684:0.014239:0.005330
therapy.   Several  prospective  trials are :@0.523634:0.521315:0.919874:0.521443:0.919874:0.505687:0.523634:0.505559:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.012430:0.005330:0.007031:0.009583:0.012508:0.010660:0.012508:0.005792:0.013143:0.003848:0.005330:0.007033:0.013123:0.005715:0.012604:0.007466:0.013123:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.005330:0.007029:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.012373:0.013143:0.005713:0.012508:-0.195545
11:@0.602099:0.515824:0.614529:0.515824:0.614529:0.506639:0.602099:0.506639:0.006215:0.006215
ongoing, evaluating the dosimetry, safety :@0.523633:0.537795:0.919859:0.537795:0.919859:0.522039:0.523633:0.522039:0.012604:0.011738:0.012950:0.012604:0.003848:0.011738:0.012950:0.005330:0.006163:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.006523:0.003848:0.011738:0.012950:0.006177:0.006523:0.011738:0.012508:0.006177:0.013181:0.012604:0.007466:0.003848:0.018049:0.012508:0.006523:0.005792:0.010314:0.005330:0.006177:0.007466:0.013143:0.006042:0.012508:0.006523:0.010314:0.005330
and efficacy of Lu-177 or Ac-255 labelled :@0.523633:0.554146:0.919874:0.554146:0.919874:0.538390:0.523633:0.538390:0.013143:0.011738:0.013181:0.006583:0.012508:0.006042:0.004686:0.004686:0.012450:0.013143:0.012450:0.010314:0.006585:0.012604:0.006042:0.006581:0.008890:0.011699:0.006388:0.010660:0.010660:0.010660:0.006591:0.012604:0.005792:0.006573:0.014239:0.012450:0.006388:0.010660:0.010660:0.010660:0.006594:0.003848:0.013143:0.013123:0.012508:0.003848:0.003848:0.012508:0.013181:0.005330
PSMA for radioligand therapy of mCRPC.:@0.523633:0.570497:0.902112:0.570497:0.902112:0.554741:0.523633:0.554741:0.011392:0.009583:0.017684:0.014239:0.004868:0.006042:0.012604:0.005792:0.004868:0.005792:0.013143:0.013181:0.003848:0.012604:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.004868:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.004868:0.012604:0.006042:0.004868:0.018049:0.015644:0.011680:0.011392:0.015644:0.005330
10:@0.902110:0.564895:0.914540:0.564895:0.914540:0.555709:0.902110:0.555709:0.006215:0.006215
RADIONUCLIDE THERAPY  :@0.523636:0.603874:0.810538:0.603874:0.810538:0.584277:0.523636:0.584277:0.013641:0.017404:0.016463:0.006585:0.019756:0.017404:0.015052:0.018344:0.010348:0.006585:0.016463:0.012230:0.006585:0.009878:0.015993:0.012230:0.013641:0.017404:0.013170:0.014581:0.006562:0.006585
OF BONE METASTASES:@0.523636:0.623164:0.767758:0.623164:0.767758:0.603567:0.523636:0.603567:0.019756:0.011289:0.006585:0.013641:0.019756:0.017404:0.012230:0.006585:0.021167:0.012230:0.009878:0.017404:0.012230:0.009878:0.017404:0.012230:0.012230:0.012230
Bone is a common  site of metastases in :@0.523636:0.641821:0.919885:0.641821:0.919885:0.626065:0.523636:0.626065:0.011045:0.012604:0.011738:0.012508:0.009102:0.003848:0.007466:0.009102:0.013143:0.009102:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.005330:0.003762:0.007466:0.003848:0.006523:0.012508:0.009102:0.012604:0.006042:0.009102:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.009102:0.003848:0.011738:0.005330
several tumours. Presence of skeletal me-:@0.523636:0.658172:0.914530:0.658172:0.914530:0.642416:0.523636:0.642416:0.007466:0.012508:0.010660:0.012508:0.005792:0.013143:0.003848:0.006889:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330:0.006879:0.011392:0.005709:0.012508:0.007466:0.012508:0.011738:0.012450:0.012508:0.006889:0.012604:0.006042:0.006889:0.007466:0.009660:0.012508:0.003848:0.012508:0.006523:0.013143:0.003848:0.006889:0.018049:0.012508:0.006388
tastases is associated with the occurrence :@0.523636:0.674523:0.919862:0.674523:0.919862:0.658767:0.523636:0.658767:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.004849:0.003848:0.007466:0.004849:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.004849:0.015990:0.003848:0.006523:0.011738:0.004849:0.006523:0.011738:0.012508:0.004849:0.012604:0.012450:0.012450:0.011699:0.005792:0.005702:0.012508:0.011738:0.012450:0.012508:0.005330
of skeletal-related events (SREs), morbidity, :@0.523636:0.690875:0.919866:0.690875:0.919866:0.675119:0.523636:0.675119:0.012604:0.006042:0.004083:0.007466:0.009660:0.012508:0.003848:0.012508:0.006523:0.013143:0.003848:0.006388:0.005717:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.004087:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.004085:0.007100:0.009583:0.011680:0.010314:0.007466:0.007100:0.005330:0.004089:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006523:0.010314:0.005330:0.005330
drastic reduction in the quality of life and :@0.523636:0.707226:0.919875:0.707226:0.919875:0.691470:0.523636:0.691470:0.013181:0.005792:0.013143:0.007466:0.006523:0.003848:0.012450:0.006639:0.005713:0.012508:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.006625:0.003848:0.011738:0.006639:0.006523:0.011738:0.012508:0.006625:0.013123:0.011699:0.013143:0.003848:0.003848:0.006523:0.010314:0.006639:0.012604:0.006042:0.006629:0.003848:0.003848:0.006042:0.012508:0.006639:0.013143:0.011738:0.013181:0.005330
death. Bone metastases are therefore de-:@0.523636:0.723577:0.914561:0.723577:0.914561:0.707821:0.523636:0.707821:0.013181:0.012508:0.013143:0.006523:0.011738:0.005330:0.005299:0.011045:0.012604:0.011738:0.012508:0.005296:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005311:0.013143:0.005715:0.012508:0.005311:0.006523:0.011738:0.012508:0.005709:0.012508:0.006042:0.012604:0.005705:0.012508:0.005311:0.013181:0.012508:0.006388
serving of prompt institution of effective :@0.523636:0.739928:0.919891:0.739928:0.919891:0.724172:0.523636:0.724172:0.007466:0.012508:0.005792:0.010660:0.003848:0.011738:0.012950:0.010006:0.012604:0.006042:0.010006:0.013123:0.005715:0.012604:0.018049:0.013123:0.006523:0.010006:0.003848:0.011738:0.007466:0.006523:0.003848:0.006523:0.011699:0.006523:0.003848:0.012604:0.011738:0.010006:0.012604:0.006042:0.010006:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.005330
therapy aimed at alleviating  pain and :@0.523636:0.756280:0.919870:0.756280:0.919870:0.740524:0.523636:0.740524:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.012277:0.013143:0.003848:0.018049:0.012508:0.013181:0.012277:0.013143:0.006523:0.012277:0.013143:0.003848:0.003848:0.012508:0.010660:0.003848:0.013143:0.006523:0.003848:0.011738:0.012950:0.005330:0.006960:0.013123:0.013143:0.003848:0.011738:0.012277:0.013143:0.011738:0.013181:0.005330
preventing the occurrence  of complica-:@0.523636:0.772631:0.914561:0.772631:0.914561:0.756875:0.523636:0.756875:0.013123:0.005715:0.012508:0.010660:0.012508:0.011738:0.006523:0.003848:0.011738:0.012950:0.008601:0.006523:0.011738:0.012508:0.008601:0.012604:0.012450:0.012450:0.011699:0.005792:0.005702:0.012508:0.011738:0.012450:0.012508:0.005330:0.003262:0.012604:0.006042:0.008601:0.012450:0.012604:0.018049:0.013123:0.003848:0.003848:0.012450:0.013143:0.006388
tions. For decades, radionuclides such as :@0.523636:0.788982:0.919881:0.788982:0.919881:0.773226:0.523636:0.773226:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.007331:0.009333:0.012604:0.005792:0.007318:0.013181:0.012508:0.012450:0.013143:0.013181:0.012508:0.007466:0.005330:0.007331:0.005792:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.007466:0.007331:0.007466:0.011699:0.012450:0.011738:0.007331:0.013143:0.007466:0.005330
Phosphorus-32, Strontium-89, and more re-:@0.523636:0.805333:0.914553:0.805333:0.914553:0.789577:0.523636:0.789577:0.011392:0.011738:0.012604:0.007466:0.013123:0.011738:0.012604:0.005792:0.011699:0.007466:0.006388:0.010660:0.010660:0.005330:0.005349:0.009583:0.006523:0.005711:0.012604:0.011738:0.006523:0.003848:0.011699:0.018049:0.006388:0.010660:0.010660:0.005330:0.005349:0.013143:0.011738:0.013181:0.005349:0.018049:0.012604:0.005709:0.012508:0.005349:0.005713:0.012508:0.006388
cently Samarium-153 EDTMP, Rhenium-186 :@0.523636:0.821685:0.919866:0.821685:0.919866:0.805929:0.523636:0.805929:0.012450:0.012508:0.011738:0.006523:0.003848:0.010314:0.005780:0.009583:0.013143:0.018049:0.013143:0.005792:0.003848:0.011699:0.018049:0.006388:0.010660:0.010660:0.010660:0.005792:0.010314:0.014316:0.008197:0.017684:0.009021:0.005330:0.005778:0.011680:0.011738:0.012508:0.011738:0.003848:0.011699:0.018049:0.006388:0.010660:0.010660:0.010660:0.005330
HEDP and Rhenium 188 HEDP have been :@0.523636:0.838036:0.919887:0.838036:0.919887:0.822280:0.523636:0.822280:0.013143:0.010314:0.014316:0.011392:0.007235:0.013143:0.011738:0.013181:0.007222:0.011680:0.011738:0.012508:0.011738:0.003848:0.011699:0.018049:0.007224:0.010660:0.010660:0.010660:0.007235:0.013143:0.010314:0.014316:0.011392:0.007224:0.011738:0.013143:0.010660:0.012508:0.007226:0.013123:0.012508:0.012508:0.011738:0.005330
successfully used in the targeted therapy :@0.523636:0.854387:0.919891:0.854387:0.919891:0.838631:0.523636:0.838631:0.007466:0.011699:0.012450:0.012450:0.012508:0.007466:0.007466:0.006042:0.011699:0.003848:0.003848:0.010314:0.007247:0.011699:0.007466:0.012508:0.013181:0.007235:0.003848:0.011738:0.007235:0.006523:0.011738:0.012508:0.007226:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.012508:0.013181:0.007235:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
of bone metastases, with effective pain :@0.523636:0.870738:0.919872:0.870738:0.919872:0.854982:0.523636:0.854982:0.012604:0.006042:0.009814:0.013123:0.012604:0.011738:0.012508:0.009814:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005330:0.009814:0.015990:0.003848:0.006523:0.011738:0.009814:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.009814:0.013123:0.013143:0.003848:0.011738:0.005330
control and tolerable side effects. The :@0.523636:0.887090:0.919899:0.887090:0.919899:0.871334:0.523636:0.871334:0.012450:0.012604:0.011738:0.006523:0.005703:0.012604:0.003848:0.013027:0.013143:0.011738:0.013181:0.013027:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.013027:0.007466:0.003848:0.013181:0.012508:0.013027:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330:0.013027:0.008197:0.011738:0.012508:0.005330
use of these beta-emitting radionuclides :@0.523636:0.903441:0.919875:0.903441:0.919875:0.887685:0.523636:0.887685:0.011699:0.007466:0.012508:0.009217:0.012604:0.006042:0.009217:0.006523:0.011738:0.012508:0.007466:0.012508:0.009217:0.013123:0.012508:0.006523:0.013143:0.006388:0.012508:0.018049:0.003848:0.006523:0.006523:0.003848:0.011738:0.012950:0.009217:0.005792:0.013143:0.013181:0.003848:0.012604:0.011738:0.011699:0.012450:0.003848:0.003848:0.013181:0.012508:0.007466:0.005330
alone, while very effective in pain control, :@0.523636:0.919792:0.919858:0.919792:0.919858:0.904036:0.523636:0.904036:0.013143:0.003848:0.012604:0.011738:0.012508:0.005330:0.005523:0.015990:0.011738:0.003848:0.003848:0.012508:0.005523:0.010660:0.012508:0.005792:0.010314:0.005523:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.005523:0.003848:0.011738:0.005523:0.013123:0.013143:0.003848:0.011738:0.005523:0.012450:0.012604:0.011738:0.006523:0.005702:0.012604:0.003848:0.005330:0.005330
does not confer survival benefit.:@0.523636:0.936143:0.820931:0.936143:0.820931:0.920387:0.523636:0.920387:0.013181:0.012604:0.012508:0.007466:0.005330:0.011738:0.012604:0.006523:0.005330:0.012450:0.012604:0.011738:0.006042:0.012508:0.005792:0.005330:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330